Swedish Orphan Biovitrum AB
https://www.sobi.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Swedish Orphan Biovitrum AB
Deal Watch: Merck KGAA Teams With AI Biotechs On Drug Discovery Efforts
Plus deals involving Debiopharm/SunRock, RefleXion/3B Pharmaceuticals, Pharmanovia/Sanofi and more.
GSK’s Ojjaara Scores Myelofibrosis Nod After Round-The-World Journey
The US FDA approved the JAK inhibitor momelotinib for myelofibrosis with anemia, with an analyst forecasting peak sales of more than $425m.
Japan Sets Luxturna, Other New Prices While Cutting Selected Fast Growers
Six new drugs including Luxturna will be price-listed in Japan on 30 August, with the Novartis gene therapy set to become the second-most expensive therapeutic product in the country. Behind another round of market expansion-related price cuts for selected drugs, discussions on possible changes to the repricing system are ongoing.
Finance Watch: Mallinckrodt Bankruptcy Enables Debt, Opioid Pact Payouts
Public Company Edition: Mallinckrodt entered into a restructuring support agreement with most of its debt holders and will de-list. Also, Aprinoia no longer plans to go public in a SPAC merger and Novartis, Agenus and Aravive revealed job cuts.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Akinion Pharmaceuticals AB
- Arexis AB
- Biovitrum AB
- Dova Pharmaceuticals, Inc.
- Sobi, Inc.
- Swedish Orphan International Holding AB
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice